$0.26
0.73% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US38000Q1022
Symbol
GLYC
Sector
Industry

GlycoMimetics, Inc. Stock price

$0.26
+0.04 18.95% 1M
-0.07 20.70% 6M
+0.01 5.10% YTD
-0.03 9.42% 1Y
-0.35 57.31% 3Y
-2.92 91.77% 5Y
-8.48 97.01% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.00 0.73%
ISIN
US38000Q1022
Symbol
GLYC
Sector
Industry

Key metrics

Market capitalization $16.89m
Enterprise Value $11.28m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 5.00
Revenue growth (TTM) Revenue growth -100.00%
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-23.79m
Free Cash Flow (TTM) Free Cash Flow $-25.70m
Cash position $5.61m
EPS (TTM) EPS $-0.46
Short interest 3.44%
Show more

Is GlycoMimetics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

GlycoMimetics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast GlycoMimetics, Inc.:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast GlycoMimetics, Inc.:

Hold
100%

Financial data from GlycoMimetics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 0.02 0.02
96% 96%
-
-0.02 -0.02
96% 96%
-
- Selling and Administrative Expenses 16 16
12% 12%
-
- Research and Development Expense 8.25 8.25
60% 60%
-
-24 -24
39% 39%
-
- Depreciation and Amortization 0.02 0.02
96% 96%
-
EBIT (Operating Income) EBIT -24 -24
40% 40%
-
Net Profit -29 -29
21% 21%
-

In millions USD.

Don't miss a Thing! We will send you all news about GlycoMimetics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

GlycoMimetics, Inc. Stock News

Neutral
Business Wire
4 days ago
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of GlycoMimetics, Inc. (NasdaqGM: GLYC) and Crescent Biopharma, Inc. Pursuant to the terms of the agreement, shareholders of GlycoMimetics will own approximately 3.1% of the combined company. KSF is seeking to dete...
Neutral
GlobeNewsWire
23 days ago
Industry Veteran Brings 30 Years of Experience in Finance, Strategy and Operations WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent”), a private biotechnology company developing novel precision-engineered molecules targeting validated biology to advance care for patients with solid tumors, today announced the appointment of David Lubner to its board of dire...
Neutral
GlobeNewsWire
about 2 months ago
Jonathan McNeill, M.D., Appointed President and Chief Operating Officer Ellie Im, M.D.
More GlycoMimetics, Inc. News

Company Profile

GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.

Head office United States
CEO Harout Semerjian
Employees 26
Founded 2003
Website www.glycomimetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today